Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Notes Payables (2016 - 2021)

Sunshine Biopharma's Notes Payables history spans 8 years, with the latest figure at $1.9 million for Q4 2021.

  • For Q4 2021, Notes Payables rose 131.58% year-over-year to $1.9 million; the TTM value through Dec 2021 reached $1.9 million, up 131.58%, while the annual FY2021 figure was $1.9 million, 131.58% up from the prior year.
  • Notes Payables reached $1.9 million in Q4 2021 per SBFM's latest filing, up from $330000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.9 million in Q4 2021 to a low of $3915.0 in Q1 2018.
  • Average Notes Payables over 5 years is $380557.2, with a median of $265088.5 recorded in 2017.
  • Peak YoY movement for Notes Payables: crashed 94.52% in 2018, then surged 2678.95% in 2019.
  • A 5-year view of Notes Payables shows it stood at $596577.0 in 2017, then fell by 29.65% to $419663.0 in 2018, then soared by 39.71% to $586307.0 in 2019, then soared by 39.94% to $820454.0 in 2020, then surged by 131.58% to $1.9 million in 2021.
  • Per Business Quant, the three most recent readings for SBFM's Notes Payables are $1.9 million (Q4 2021), $330000.0 (Q3 2021), and $330000.0 (Q2 2021).